Telix Pharmaceuticals Securities Class Action Notice, Compensation Opportunity
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: Nov 27 20250mins
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Telix Pharmaceuticals securities between February 21 and August 28, 2025, that the deadline to apply as lead plaintiff is January 9, 2026, potentially allowing for compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Telix made materially false statements during the class period, overstating the progress of prostate cancer therapeutic candidates and the quality of its supply chain, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven success record to ensure effective representation in class actions, avoiding firms that lack experience and merely act as intermediaries.
TLX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What were the key regulatory issues Telix Pharmaceuticals failed to disclose?
Why did Telix's stock price drop significantly after the FDA's response?
How might the class action lawsuit impact Telix's future stock performance?
Will Telix Pharmaceuticals face additional regulatory scrutiny after the SEC investigation?